Hippocratic AI, headquartered in United States, remains privately held. Investors last valued the company at $3.5B. No public ticker exists for the company.
1 valuation. The latest, $1.6B post-money, was set by the Series B in Jan 2025.
Premji InvestLEAD
General CatalystLEAD
Obvious VenturesLEADCCraft VentureLEADAAvenir GrowthLEAD
Kleiner PerkinsLEAD
Andreessen HorowitzLEAD
CapitalGPremji InvestGeneral CatalystObvious VenturesCraft VentureHippocratic AI, founded in 2022 and headquartered in the United States, develops clinical AI systems designed for patient safety and privacy. Its generative AI healthcare agents are deployed on AWS and built on NVIDIA technology, and the company has conducted more than 250 million clinical patient interactions, testing its agents with a network of over 7,700 US licensed clinicians across 775,000 test calls.
Hippocratic AI's agents are built for health systems, payors and pharma, and the company has teamed up with KPMG's global healthcare consulting practice to help clients deploy its patient-facing AI agents. It also offers an app store letting clinicians design AI agents for patient care and operational tasks.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Hippocratic AI.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Hippocratic AI availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Hippocratic AI included.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. Hippocratic AI is a private company; its shares do not trade on a public exchange.
The last valuation is $3.5B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
